170 related articles for article (PubMed ID: 30501604)
1. MMP7 Induces T-DM1 Resistance and Leads to the Poor Prognosis of Gastric Adenocarcinoma
Li H; Xu X; Liu Y; Li S; Zhang D; Meng X; Lu L; Li Y
Anticancer Agents Med Chem; 2018; 18(14):2010-2016. PubMed ID: 30501604
[TBL] [Abstract][Full Text] [Related]
2. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
3. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.
Wang H; Wang W; Xu Y; Yang Y; Chen X; Quan H; Lou L
Cancer Sci; 2017 Jul; 108(7):1458-1468. PubMed ID: 28388007
[TBL] [Abstract][Full Text] [Related]
4. Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer.
Liu W; Yuan J; Liu Z; Zhang J; Chang J
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986466
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
6. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
7. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
8. DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway.
Chen L; Li M; Li Q; Wang CJ; Xie SQ
Mol Cancer; 2013 Dec; 12():157. PubMed ID: 24325363
[TBL] [Abstract][Full Text] [Related]
9. Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway.
Wang Z; Ma LJ; Kang Y; Li X; Zhang XJ
Oncol Rep; 2015 Mar; 33(3):1097-106. PubMed ID: 25573172
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of GPR34 expression affects the progression and prognosis of human gastric adenocarcinoma by PI3K/PDK1/AKT pathway.
Yu W; Ma S; Wang L; Zuo B; Li M; Qiao Z; Pan X; Liu Y; Wang J
Histol Histopathol; 2013 Dec; 28(12):1629-38. PubMed ID: 23836308
[TBL] [Abstract][Full Text] [Related]
11. miR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells.
Jia X; Li N; Peng C; Deng Y; Wang J; Deng M; Lu M; Yin J; Zheng G; Liu H; He Z
Oncotarget; 2016 Feb; 7(6):7044-54. PubMed ID: 26799283
[TBL] [Abstract][Full Text] [Related]
12. Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance.
Zuo Q; Liu J; Zhang J; Wu M; Guo L; Liao W
Sci Rep; 2015 Jun; 5():11634. PubMed ID: 26108989
[TBL] [Abstract][Full Text] [Related]
13. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
Sabbaghi M; Gil-Gómez G; Guardia C; Servitja S; Arpí O; García-Alonso S; Menendez S; Arumi-Uria M; Serrano L; Salido M; Muntasell A; Martínez-García M; Zazo S; Chamizo C; González-Alonso P; Madoz-Gúrpide J; Eroles P; Arribas J; Tusquets I; Lluch A; Pandiella A; Rojo F; Rovira A; Albanell J
Clin Cancer Res; 2017 Nov; 23(22):7006-7019. PubMed ID: 28821558
[No Abstract] [Full Text] [Related]
14. Wnt/β-Catenin Signaling Activation beyond Robust Nuclear β-Catenin Accumulation in Nondysplastic Barrett's Esophagus: Regulation via Dickkopf-1.
Lyros O; Rafiee P; Nie L; Medda R; Jovanovic N; Otterson MF; Behmaram B; Gockel I; Mackinnon A; Shaker R
Neoplasia; 2015 Jul; 17(7):598-611. PubMed ID: 26297437
[TBL] [Abstract][Full Text] [Related]
15. Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1).
Sung M; Tan X; Lu B; Golas J; Hosselet C; Wang F; Tylaska L; King L; Zhou D; Dushin R; Myers JS; Rosfjord E; Lucas J; Gerber HP; Loganzo F
Mol Cancer Ther; 2018 Jan; 17(1):243-253. PubMed ID: 29054985
[TBL] [Abstract][Full Text] [Related]
16. The Wnt3a/β-catenin/TCF7L2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab.
Shen G; Gao Q; Liu F; Zhang Y; Dai M; Zhao T; Cheng M; Xu T; Jin P; Yin W; Huang D; Weng H; Chen W; Ren H; Mu X; Wu X; Hu S
Biochem Biophys Res Commun; 2020 Jun; 526(3):685-691. PubMed ID: 32248976
[TBL] [Abstract][Full Text] [Related]
17. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
18. Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.
Dey N; Young B; Abramovitz M; Bouzyk M; Barwick B; De P; Leyland-Jones B
PLoS One; 2013; 8(10):e77425. PubMed ID: 24143235
[TBL] [Abstract][Full Text] [Related]
19. Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells.
Chung YC; Chang CM; Wei WC; Chang TW; Chang KJ; Chao WT
Sci Rep; 2018 Mar; 8(1):3930. PubMed ID: 29500444
[TBL] [Abstract][Full Text] [Related]
20. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer.
Liu G; Jiang C; Li D; Wang R; Wang W
Tumour Biol; 2014 Oct; 35(10):9801-6. PubMed ID: 24981249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
